Cohance Lifesciences Sees Sharp Decline in Q1 Revenue and Profit
The CDMO reported a 25.6% YoY revenue drop and a 97.3% profit plunge, with net profit margin shrinking to just 0.4%.
Cohance Lifesciences' Q1 FY27 results show a steep contraction, with revenue and profit falling sharply both year-on-year and sequentially.
Cohance Lifesciences reported a sharp contraction in its Q1 FY27 results, with both revenue and profit falling significantly compared to last year and the previous quarter. The pharmaceutical CDMO's net profit margin collapsed, indicating severe pressure on profitability.
The company's revenue for the quarter ended June 2026 stood at ₹359.89 crore, a 25.6% decline from the same quarter last year and a 36.6% drop from the March 2026 quarter. Profit after tax fell even more dramatically, plunging 97.3% year-on-year and 95.9% sequentially to just ₹1.41 crore. This resulted in a net profit margin of only 0.4%, down from 10.9% in Q1 FY26 and 6.1% in the previous quarter.
A look at the last five quarters reveals a clear downward trajectory in profitability, even as revenue had shown some resilience until the recent sharp drop.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Period | Quarter ended June 2026 | Quarter ended March 2026 | Quarter ended June 2025 |
| Revenue (₹ Cr) | 359.89YoY -26% | 567.55 | 483.58 |
| Profit (₹ Cr) | 1.41YoY -97% | 34.56 | 52.57 |
| Net Profit Margin (%) | 0.4YoY -96% | 6.1 | 10.9 |
Despite the weak quarterly performance, the company's trailing twelve-month (TTM) figures offer a slightly better picture, with a net profit margin of 9.3% on revenue of ₹1,906.81 crore. The balance sheet remains strong, with a low debt-to-equity ratio of 0.05 and a healthy interest coverage ratio of 28.85.
The stock has reflected these challenges, declining 53.1% over the past year to close at ₹438.9 on the results date. This weak earnings performance is mirrored in the valuation, where the stock trades at a significant premium to the industry, with a P/E of 110.2 compared to the sector average of 37.2. The immediate focus for the company will be on stabilizing its quarterly earnings to align with its stronger annual and TTM fundamentals.
Live Chart
· COHANCE
(BSE)
ISIN: INE03QK01018
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.